Eight Startups Selected to Innovate Women's Heart and Brain Health Through Technology
TL;DR
Eight innovative companies gain a competitive edge by joining the American Heart Association's Heart and Brain Health Accelerator, offering them mentorship, funding, and industry visibility.
The American Heart Association's Heart and Brain Health Accelerator selects eight companies with technologies like AI diagnostics and non-invasive therapies to improve cardiovascular and brain health outcomes.
This initiative by the American Heart Association aims to transform lives by advancing technologies that promise to make heart and brain health care more accessible and effective.
Discover how eight cutting-edge companies are leveraging AI and non-invasive tech to revolutionize heart and brain health care, from mobile thermal imaging to spinal cord stimulation.
Found this article helpful?
Share it with your network and spread the knowledge!
The American Heart Association, in collaboration with American Heart Association Ventures and the Center for Health Technology and Innovation, has announced the selection of eight startups to participate in the Heart and Brain Health Accelerator. This initiative is designed to foster innovation in medical and digital health technologies that can enhance patient outcomes, reduce healthcare costs, and eliminate barriers to care, particularly in the realm of women's heart and brain health.
Lisa Suennen, managing partner of American Heart Association Ventures, emphasized the importance of innovation in combating heart disease and stroke. The accelerator program provides selected companies with mentorship, funding, and access to a network of experts, aiming to expedite the development of their technologies from concept to real-world application.
The startups, including Kelvin Health and LightHearted AI Health, are developing solutions ranging from non-invasive diagnostics for vascular diseases to contactless heart condition detection devices. Other participants like MOMM Diagnostics and Powerful Medical are focusing on early detection of preeclampsia in pregnancy and AI-assisted interpretation of electrocardiograms, respectively. Reach Neuro and Sinaptica Therapeutics are working on technologies to aid stroke survivors and slow Alzheimer's disease progression, while SynchNeuro and Veravas are innovating in blood sugar monitoring and disease detection through biomarker purification.
These companies will also join the MedTech Innovator program, gaining additional resources and visibility within the medical technology industry. They will have the opportunity to compete in the MedTech Innovator Competition Finals, further showcasing their potential to revolutionize healthcare.
The selection process was overseen by a committee of expert volunteers from the American Heart Association, including notable figures in cardiology and medical technology. This initiative underscores the Association's commitment to leveraging technology for healthier lives and represents a significant step forward in addressing the unique health challenges faced by women.
Curated from NewMediaWire
